No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Chinese Takeovers

SF

Thanks for posting that article. Hepalink's >40% investment in RVX is perilously close to controlling RVX and it's IP.  A disconcerting situation. I trust that DM has the situation under control. 

Chicagoest   

Share
New Message
Please login to post a reply